Table 3.

Determination of initial (t_½α) and terminal (t_½β) half-lives as well as of drug exposure (area under the curve; AUC) of the parental antibodies and bispecific Dab-Fc 2 × 3 molecule

	t½α [h]		t½β [h]		AUC [pmol/ml·h]
	HER2	HER3	HER2	HER3	HER2	HER3
Trastuzumab	0.46 ± 0.36	-	117 ± 22	-	9,812 ± 2,030	-
IgG 3–43	-	1.9 ± 1.8	-	60 ± 32	-	3,898 ± 1,922
Dab-Fc 2x3	0.95 ± 0.47	1.5 ± 0.8	94 ± 4	222 ± 73	9,684 ± 3,779	16,145 ± 4,664

-: not performed; Mean ± SD, n = 3.